CMS Proposes $90B Medicare Anti-Fraud Rule; Humana Slides 13%
HUM has more than doubled off its 52-week low of $163.11 on elevated volume (2.9× avg).
Summary
CMS proposed a sweeping anti-fraud rule Tuesday that it says could save taxpayers nearly $90 billion over 10 years, and the main hit to insurers is tougher Medicare Advantage Risk Adjustment Data Validation audits used to claw back improper payments tied to unsupported diagnosis data. Humana took the brunt of it, closing the regular session down 12.98% at $385.78 before slipping another 0.46% to $384.00 after hours. That is a violent reaction for a company whose Q3 10-Q already showed a $303 million Insurance segment operating loss on a 93.9% benefit ratio, so any threat to risk-adjustment revenue lands on an already thin margin. The rule is only a proposal at this stage, meaning the comment period and final rule language will determine how aggressive the audit recoveries actually become.
At the time of this announcement, HUM was trading at $384.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $46.3B. The 52-week trading range was $163.11 to $462.87. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Benzinga.